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Abstract 
Aging is associated with the loss of preferential urinary excretion of Amadofi-product glycated albumin. We have measured the 
binding of ~25I-labeled glycated albumin to the renal brush-border membrane vesicles from young and old rats to determine whether a 
specific receptor-mediated endocytosis ystem may be involved. 125I-Glycated albumin was specifically bound by renal brush-border 
membrane vesicles in a time- and temperature-dependent manner; the binding was concentration-dependent, saturable and reversible. 
Scatchard plots gave an apparent dissociation constant K m of 488 _+ 17 nM, and a number of binding sites N of 33.5 +_ 3.4 pmol/mg 
protein/min in membrane vesicles from young (3 months old) rats; the binding of native [~25I]albumin, gave a K m of 1194 ± 200 nM 
(P < 2%) and N of 82.4 _+ 16.3 pmol/mg protein/min (P < 3%). Vesicles from 10-month-old rats had a similar K m (619.6 _+ 135.3 
nM) and N (21.91 _+ 2.98 pmol/mg protein/min), while those from older (30 months old) rats had significantly increased K m 
(1344 + 237 nM, P < 3%) and N (81.3 _+ 10.9 pmol/mg protein/min, P < 1%) for 125I-glycated albumin binding. 125I-Glycated HSA 
was not displaced by unlabeled native HSA in less than 100-fold excess and native [~25I]HSA was only displaced by a 10-fold excess of 
unlabeled glycated HSA. The binding of native [125I]HSA was partly inhibited (85%) by unlabeled glycated HSA. Thus, there appear to 
be two different binding sites, one for glycated and the other for native albumin, lying close together; and the glycation site on albumin is 
the discriminatory ecognition factor. 
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I. Introduction 
Glycation of proteins, especially the main circulating 
protein albumin, normally occurs very slowly under 
physiological conditions [1,2]. But the impaired glucose 
tolerance that is associated with aging [3,4] leads to more 
rapid glycation and a significant increase in the fraction of 
albumin that is glycated [5]. There is good evidence that 
glycation alters the physicochemical properties of albumin 
[6,7], affecting both its functional properties and its renal 
handling [8]. Glycation of albumin increases its permeabil- 
ity across the glomerular basement membrane [9,10] and 
impairs its tubular reabsorption [11,12]. The increase in 
negative charge following glycation [8,13] is believed to be 
one of the main reasons for its altered recognition [14]. 
Glycated albumin is not reabsorbed, while native albumin 
is efficiently reabsorbed by the proximal tubule when the 
glomerular filtration rate is normal. Indeed, recent studies 
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have shown that this glycated albumin is preferentially 
excreted in the urine by young normal humans [15] and 
rats [5,8,16]. 
This discriminatory excretion, or editing, is gradually 
lost with aging in humans [15] and rats [5], due to dilution 
of the excreted glycated albumin with native albumin, 
while a significant proteinuria develops mainly due to 
albumin leakage [17]. Several reports claim that the 
glomerular leakage of albumin with aging results from an 
alteration in glomerular size-perm selectivity because of 
increased transcapillary pathways and/or  a loss of electri- 
cal sieving. It could also be due to a change in capillary 
hemodynamics [18,19]. Whatever the precise mechanism 
responsible for this increased glomerular permeability, it
could not yield the dramatic decline in the editing ratio 
that occurs in elderly rats [5] unless there was an increase 
in the tubular reabsorption of glycated albumin by some 
alternative system, even when the reabsorptive capacity for 
native albumin is overloaded. We have therefore postu- 
lated the existence of a receptor-mediated endocytosis 
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system specific for Amadori-product glycated albumin in 
the convoluted proximal tubule cells. This system would 
develop with age and be capable of collecting that ligand, 
much like several other ligands. For example, aldehyde- 
modified albumin is taken up by a receptor-mediated 
process [20]. The basic requirement for endocytosis of 
glycated albumin is thus a specific site. 
This study provides evidence for the existence of spe- 
cific binding sites for Amadori-product glycated albumin 
on renal brush-border membrane vesicles that are different 
from a native albumin binding system. The receptor-medi- 
ated endocytosis system is described, and the competition 
between native and glycated albumins were examined 
using the rapid filtration technique. 
2. Materials and methods 
sodium azide, 1 mM PMSF, 5 mM EDTA, 1 mM NEM 
and incubated without (native control HSA), or with 0.5 M 
glucose at 37°C in the dark for 1, 2, 3 or 5 days [26]. The 
samples were then extensively dialyzed against 0.25 M 
ammonium acetate/0.05 M MgC12 (pH 8.5) at 4°C to 
remove free glucose. Amadori-product glycated albumin 
(AP-HSA) was separated from nonglycated albumin (na- 
tive HSA) by affinity chromatography on a column of 
phenyl-boronate (Glyco-Gel B from Pierce) [27] and the 
percentage of glycated albumin determined according to 
the manufacturer. The extent of glycation was determined 
by measuring the amount of formaldehyde released by 
periodate oxidation of cl hydroxyls in the Amadori-prod- 
uct form of the glycated albumin, using the method of 
Ahmed and Furth [28]; results are expressed as mol 
HCHO/mol albumin. The percentage of glycated albumin 
2.1. Isolation of renal brush-border membrane vesicles 
Renal brush-border membrane vesicles (RBBMV) were 
prepared from the cortexes of individual paired kidneys of 
young (3 months old) and older (10 and 30 months old) 
rats killed by decapitation. Studies were performed on 
male Wistar rats (WAG/Rij), as this strain does not suffer 
from age-associated nephropathy [21]. The kidneys were 
removed, decapsulated, placed in ice-cold buffer (300 mM 
D-mannitol, 12 mM Tris-HC1 (pH 7.4)) and processed at 
4°C. Membranes were fractionated by the MgC12 precipi- 
tation method [22], and the final brush-border membrane 
preparation thus obtained was resuspended in 300 mM 
mannitol, 10 mM Hepes-Tris (pH 7.4). Aliquots (200 /xl) 
of brush-border membranes (3 mg/ml) were stored in 
liquid nitrogen until used. 
2.2. Quantitative protein and enzyme assay 
Protein was determined by the Lowry method with BSA 
as standard [23]. The marker enzymes for preparation 
assessment were amino peptidase (EC 3.4.11.2) and 
Na+/K + ATPase (EC 3.6.1.3), whose activities were 
assayed by the methods of Haase et al. [24] and Heller and 
Hanahan [25]. The brush-border membrane vesicles were 
routinely enriched 7.2 ___ 0.09 (n = 7) times in amino pep- 
tidase and 0.45 -4- 0.04 (n = 7) in Na+/K ÷ ATPase over 
the homogenate in rats of all three age groups. 
2.3. Preparation and purification of Amadori-product gly- 
cated albumin 
Iodinated human serum albumin ([125I]HSA, specific 
activity 25 /xCi/mg) was from Sorin Biomedica (Italy), 
human and bovine unlabeled serum albumin (fraction V) 
were from Sigma (USA), and lysozyme (EC 3.2.1.17) was 
from Miles (France). Unlabeled HSA was dissolved in 
phosphate-buffered saline (PBS; pH 7.4) containing 0.02% 
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Fig. 1. Time course of [125I]AP-HSA binding to renal brush-border 
membrane v sicles from young (3-month-old) rats. Membrane vesicles 
(50 ~g/ml) were incubated at37°C (A) or 4°C (B) with [1251]AP-HSA 
(14.9 nM) until indicated time. Data show specific binding and represent 
mean -4- S.E. of three assays carried out in triplicate. 
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depended on the incubation time, and varied from 56.40 ___ 
4.65 (1 day) to 85 .8+ 10.55 (2 days), 92.30+3.11 (3 
days) and 96.15 ___ 1.86 (5 days) (n = 3). The mean extent 
of glycation was 2.40 + 0.57 mol HCHO/mol  albumin for 
the whole period of incubation, while control HSA had 
0.79 __. 0.09 mol HCHO/mol  albumin. Subsequent experi- 
ments used glycated labeled and unlabeled HSA incubated 
for 5 days. Samples of glycated albumin were prepared by 
boronate chromatography, dialyzed against kinetic buffer 
(10 mM Hepes-Tris, 150 mM NaC1 (pH 7.4)), concen- 
trated in an Amicon cell, and the protein content measured. 
Aliquots of [125I]AP-HSA and [125I]HSA (5 /zg) were 
analyzed by SDS-PAGE electrophoresis on 10% acryl- 
amide gel and autoradiographed. 
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Fig. 2. Specific binding of [125I]AP-HSA (A) and 125I-HSA (B) (pmol/mg protein/min) to renal brush-border membrane vesicles from young 
(3-month-old) rats. Each point is the mean of five representative assays carried out in triplicate. Inset: Scatchard plot (B/F as a function of B). 
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2.4. Binding [125I]AP HSA and [125I]HSA to RBBMV 
Binding was measured by the rapid filtration technique 
[29]. All assays were performed in BSA-coated glass tubes 
(10 g/ l )  and the filters were presoaked in stop solution 
(kinetic buffer + 2% BSA) to reduce non-specific retention 
of labeled ligand on the filter. About 5 /xg renal brush- 
border membrane vesicles from paired batches of kidneys 
were suspended in 50/xl kinetic buffer (10 mM Hepes-Tris, 
150 mM NaC1 (pH 7.4)) and preincubated for 10 min at 
37°C or 4°C for time course study. Ligand (labeled AP- 
HSA) plus 13.7 nM cationic lysozyme (total volume 100 
/~1) was then added to initiate the binding and incubation 
was continued until the indicated time. The binding kinetic 
parameters were determined in assays performed at 37°C 
for 5 rain (final ligand labeled AP-HSA and HSA concen- 
tration 74-800 nM). The reaction was stopped by adding 2 
ml ice-cold stop solution, and the mixture was rapidly 
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Fig. 3. Specific binding of [125I]AP-HSA to renal brush-border membrane vesicles from 10-month- (A) or 30-month- (B) old rats. Each point is the mean 
of five representative measurements carried out in triplicate. Inset: Scatchard plot (B /F  as a function of B). 
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filtered (0.45-/zm pore size, cellulose filter type HAWPO 
25; Millipore) under vacuum. The tubes were rinsed with 4 
ml ice-cold stop solution and the rinse passed through the 
filter. The filters were processed for liquid scintillation 
counting. Specific binding was obtained by subtracting the 
blank value from an assay in which the renal brush-border 
membrane vesicles were preincubated with excess unla- 
beled ligand (500-times the ~25-I-labeled ligand concentra- 
tion) before adding ~25I-ligand (non-specific binding) from 
the total binding data. At least two experiments on the 
binding of [125I]AP-HSA and [Ie5I]HSA by brush-border 
membrane vesicles from young rats (3-month) were per- 
formed in parallel. 
The competitive binding of [125I]AP-HSA with HSA, 
[125I]HSA with AP-HSA and AP-HSA with [a25I]HSA was 
also investigated. ~25I-Ligand (298 nM) was incubated for 
5 min at 37°C with 5 /~g RBBMV. Unlabeled AP-HSA or 
HSA (at 1-, 10-, 100-, and 1000-fold concentrations) was 
then added and incubation continued for a further 5 min. 
The reaction was stopped and the radioactivity on filters 
was counted as above. Each assay was run in triplicate. 
2.5. Calculations 
Means, standard errors and regression analyses were 
calculated by the method of least squares and used for 
statistical analysis. Differences among means were tested 
for statistical significance (P  < 0.05) using Student's paired 
t-test. 
[125I]AP-HSA by RBBVM was appreciably slower and did 
not reach a plateau after 120 min of incubation, corre- 
sponding to 50% of the maximum binding at that time 
(Fig. 1B). Nevertheless, the initial binding rate was quite 
rapid even at 4°C, as can be seen by the earliest ime point. 
Subsequent experiments focused on how the parameters of
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3. Resul ts  
3.1. Preparation and purification of AP-glycated HSA 
Phenyl-boronate agarose was used to separate glycated 
from nonglycated human albumin (HSA). 87% of the 
125I-labeled HSA incubated with 0.5 M glucose for 5 days 
was glycated and bound by the phenyl-boronate column. 
Less than 1.9% of the control mSI-labeled HSA was bound. 
The bound material was used as labeled AP-glycated HSA; 
it contained over 2.40 mol glucose/mol albumin, while 
the unbound fraction (less than 0.80 mol glucose/mol 
albumin) was used as native labeled HSA. Autoradiogaphy 
of labeled samples (5 /xg) separated by SDS-PAGE elec- 
trophoresis revealed a single 66 kDa band HSA monomer; 
larger and smaller bands were not detected with this 
amount (data not shown). 
3.2. Binding of [nSI]AP-HSA by renal brush-border mem- 
brane vesicles: effect of age 
In these experiments binding refers to the specific bind- 
ing. [I25I]AP-HSA bound to renal brush-border membrane 
vesicles; binding occurred rapidly at 37°C and increased 
with time up to 60 min (Fig. 1A). At 4°C, the binding of 
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Fig. 4. Displacement of [1251]AP-HSA from binding sites on renal 
brush-border membrane v sicles by increasing concentrations of native 
HSA (A) and displacement of 125I-HSA by AP-HSA (B). Data showing 
residual binding ligand expressed asa percentage of specific binding 
without competitor (100%) were determined from triplicate assays of 
three xperiments and expressed asmean + S.E. 
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[~25I]AP-HSA binding by RBBMV at 37°C for 5 min, 
varied with age. 
Specific binding, defined as the difference between 
binding without (total binding) and with (nonspecific bind- 
ing) excess unlabeled glycated albumin (500-times), in- 
creased in a dose-dependent and saturable manner (Fig. 
2A). Scatchard analysis gave a linear plot, indicating one 
affinity class of receptor (Fig. 2A, inset). The apparent 
dissociation constant (K m) and the number of binding sites 
(expressed as binding capacity, N) were 488 _+ 17 nM and 
33.5 _+ 3.41 pM/min /mg RBBMV from 3-month-old rats 
(n = 9), respectively. The binding of [125I]HSA (Fig. 2B, 
inset) gave a K m of 1194 _+ 200 nM (P < 0.01) and N of 
82.4 _+ 16.27 pM/mg/min  (P  < 0.02) (n = 7). Whereas 
the binding of [125I]AP-HSA by membrane vesicles from 
10-month-old rats did not significantly change, with K m 
of 619.6 _ 135.3 nM and N of 21.91 _+ 2.98 pM/mg/min  
(n = 6) (Fig. 3A, inset), those from older (30-month) rats 
had increased K m (1344_+ 237 nM, P<0.02)  and N 
(81.3 +_ 10.9 pM/mg/min,  P < 0.01) (n = 5) (Fig. 3B, 
inset). 
For competitive experiments, RBBMV from young rats 
were preincubated with [125I]AP-HSA for 5 min, native 
HSA (1-, 10-, 100- or 1000-fold) was then added and 
incubation continued for 5 min. [125I]AP-HSA was not 
displaced from its binding sites by less than a 100-fold 
greater concentration of cold HSA (Fig. 4A). Similarly, 
unlabeled AP-HSA did not displace [125I]HSA at less than 
10-times concentration (Fig. 4B), indicating that there are 
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Fig. 5. Inhibition of [t25I]HSA binding to renal brush-border membrane 
vesicles by AP-HSA: RBBMV were preincubated with increasing amount 
of unlabeled AP-HSA (1-, 10-, 100- or 1000-fold excess) for 5 min 
before adding aconstant amount (298 nM) of [125I]HSA and incubation 
for 5 additional minutes. Results are expressed as percentage of specific 
binding of control. Data are means +S.E. of three determinations from 
tripl icate assays. * P < 0.05, * * P < 0.01, * " * P < 0.005: s ignif icant ly 
different f rom control. 
different binding sites for AP-glycated albumin and native 
albumin. Nevertheless, preincubating RBBMV with in- 
creasing concentrations of unlabeled AP-HSA inhibited the 
binding of native [~25I]HSA by 85% (P < 0.007) as soon 
as the concentrations of the two ligands were equal (Fig. 
5). These data suggest hat the two binding sites are close 
together, with the binding of AP-HSA partly overlapping 
the neighboring binding site of native HSA. 
4. Discussion 
We have reported that Amadori-product glycated albu- 
min is preferentially excreted by young rats. This phe- 
nomenon of editing, is gradually lost with aging [5]. We 
have now attempted to elucidate this phenomenon by 
postulating the existence of a receptor-mediated en ocyto- 
sis system specific for glycated albumin. We suggest hat 
the system is developed by proximal tubular cells and is 
capable of collecting lycated albumin downstream of the 
glomemlus in old rats. 
The results described here demonstrate he existence of 
this binding system on renal brush-border membrane vesi- 
cles (RBBMV), describe its main features and analyze its 
evolution with aging. Binding of Amadori-product gly- 
cared albumin (AP-HSA) showed a time- and 
temperature-dependent increase; it occurred rapidly at 37°C 
and noticeably slower at 4°C. These properties are typical 
of protein binding by renal tubules. Although the RBBMV 
used in these experiments are vesicular in nature, the 
observed association represented binding of AP-HSA to 
the external face of the membrane vesicles rather than the 
uptake (binding plus internalization). Indeed the properties 
of the recognition sites for AP-HSA agree well with one of 
the in vivo functions of the renal brush-border membranes, 
that of mediating reabsorption of filtered small proteins by 
the tubules [30]. But this reabsorptive function implies a 
mechanism for internalizing proteins at the brush-border 
membrane surface that would be an energy-dependent 
process. The use of isolated membrane vesicles provides a 
simple experimental system devoid of the complexities of 
a whole-cell system and thus excludes the energy 
metabolism-dependent process permitting only investiga- 
tion of the binding of proteins, even if intravesicular 
transport of small molecules uch as glucose [3 l] or amino 
acids [32] has been reported. Numerous data strongly 
support this insertion [33], showing in addition that the 
degradative capacity of the RBBMV for proteins is mini- 
mized in these experimental conditions [34]. Accordingly, 
data reported here refer to membrane binding. 
Amadori-product glycated albumin is specifically bound 
by RBBMV from young rats with a number of binding 
sites, N of 33.5 _+ 3.4 pmol/mg/min and an apparent 
dissociation constant K m of 488 +_ 17 nM. These values 
are comparable to those for the renal glomerular mesangial 
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cell system which binds glycated albumin with two affinity 
classes of receptor (Km values 960 nM and 74 nM) [35]. 
These binding proteins have been found on several cell 
types, especially phagocytic ells like human monocytes 
[36] and rat macrophages [37], but also on murine aortic 
endothelial cells [38,39]. The native albumin binding sites 
on our system had lower affinity, with a K m of 1194 _ 200 
nM and an N (V m) of 82.4 + 16.3 pmol/mg/min, indicat- 
ing that epithelial tubular cells have binding sites different 
from the cellular sites of interaction with native albumin in 
their ability to selectively bind AP-glycated albumin. 
The specificity of these glycated albumin binding sites 
is evidenced by the competition experiments with native 
albumin and the lack of displacement by native albumin. 
Glycated albumin bound to RBBMV was partially dis- 
placed (15%) by a 100 × concentration f native albumin, 
which is a very unphysiological ratio. These data strongly 
suggest hat the specificity of AP-glycated albumin bind- 
ing is due to a domain in glucose-modified albumin, and is 
supported to the contrary by previous tudies howing that 
albumin binds to cell sites that recognize domains of the 
albumin molecule [40,41]. This assertion is likewise sup- 
ported by data on the ligand specificity of the cell receptor 
for glycated albumin. The glucose-modified domain de- 
fined by its immunoreactivity with a monoclonal antibody 
as the principal site of albumin glycation is responsible for 
receptor ecognition, since blocking the glycated albumin 
epitope with that monoclonal ntibody prevents its binding 
to cells [35]. That study also showed that the specificity of 
AP-glycated albumin binding is due to a domain not 
present in other glucose-modified protein, emphasizing the 
discriminatory capacity of these binding sites. The second 
important element is that AP-glycated albumin can block 
the binding of native albumin to RBBMV (85%). This 
result is inconsistent with precedent data and indicates that 
the two binding sites are probably close together. The 
bound glycated albumin may overlap the binding sites for 
native albumin. This raises the question of whether this 
phenomenon is responsible for age-related albuminuria, 
which occurs well before the albumin endocytosis system 
becomes aturated [42]. 
The binding experiment results also reveal an age-re- 
lated increase in both the maximum binding capacity (N) 
(+140%) and the apparent dissociation constant (K m) 
(+ 175%) beyond 10 months, which appears to be an age 
threshold for this strain of rat [5]. These data indicate two 
changes. One is the biological adaptation of these tubular 
cells to eliminate the increased amounts of glycated albu- 
min by increasing the number of binding sites. This im- 
plies the up-regulation of the gene encoding for this bind- 
ing protein. The other is the decrease in affinity for the 
ligand with aging, which might be a direct consequence of
changes in the receptor environment, such as glycation of 
cell membrane proteins. 
Although there is good evidence for AP-glycated albu- 
min binding sites on phagocytic cells like the macrophages 
and monocytes responsible for scavenging the glycated 
albumin, this has biological importance, more especially as 
Amadori-products are sources of noxious advanced glyca- 
tion end products, recent data also indicate that glycated 
albumin stimulates monocytes to release TNF and 1L-1. 
These cytokines may play a role in the tissue remodeling 
that occurs in the development of vascular complications 
with aging [36]. It is also now well established the noxious 
effect of AP-glycated albumin on glomerular mesangium 
expansion [35], cause of the capillary occlusion. The loca- 
tion of binding sites for glycated albumin on capillary 
endothelial cells may be important for the increased per- 
meability or enhanced transcytosis of the glycated protein. 
This microvascular leakage of glycated albumin can con- 
tribute to the pathogenesis of microangiopathy [41]. Thus, 
the ubiquity of binding sites for glycated albumin seems to 
have effects that vary with the type of cell. The physio- 
logical or pathological relevance of these newly-described 
binding sites on renal brush-border membrane vesicles 
remains to be established. 
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